Search clinical trials for: Resistant Cancer

Total 89290 results

Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Metastatic Castration-Resistant Prostate Cancer

United States, Austria, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, New Zealand, Poland, Russian Federation, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, Spain, Finland, Australia, Denmark
Sir Mortimer B. Davis - Jewish General Hospital

Recruiting

Management of Castration-Resistant Prostate Cancer With Oligometastases (PCS IX)

Castration-resistant Prostate Cancer Patients With Oligometastases

Canada
Aragon Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

Moldova, Republic of, Spain
Hunan Province Tumor Hospital

Recruiting

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Carcinoma, Non-Small Cell Lung | EGFR Gene Mutation

China
Sun Yat-sen University

Recruiting

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

Non-small Cell Lung Cancer (NSCLC) | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation | Somatic Mutation | Germline Mutations

China
Indiana University

Recruiting

Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression

Traumatic Brain Injury

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
Taiho Oncology, Inc.

Completed

Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer

France, United States, Spain, United Kingdom
M.D. Anderson Cancer Center
AstraZeneca; Aravive Biologics Inc

Active, not recruiting

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditions

United States
Allarity Therapeutics
Smerud Medical Research International AS; Lantern Pharma Inc.

Active, not recruiting

Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Metastatic Castration-Resistant Prostate Cancer Patients

Denmark
Bayer

Active, not recruiting

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States, United Kingdom, Finland
AstraZeneca

Active, not recruiting

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD)

Non-Small Cell Lung Cancer

Denmark, Italy, Spain, United States, Korea, Republic of, Japan, Netherlands, Norway, Sweden
Shattuck Labs, Inc.

Active, not recruiting

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma

United States, United Kingdom, Spain, Canada
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Metastatic Melanoma | Advanced Malignant Solid Neoplasm | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage... and other conditions

United States
Bayer

Active, not recruiting

A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described (DAROL)

Prostate Cancer

United States, Canada, Japan, Spain, Germany, Belgium, Argentina, Austria, Brazil, Greece, Italy, Russian Federation, Taiwan, China, Denmark, France, Colombia
Exelixis
Takeda; Roche-Genentech

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)

Metastatic Prostate Cancer | Prostate Adenocarcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Portugal, Russian Federation, Singapore, Spain, ... and more
Hinova Pharmaceuticals USA, Inc.

Active, not recruiting

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

Germany, Spain, Denmark, France, United Kingdom, Russian Federation, Poland, Australia, Italy, Netherlands, United States, Finland, Canada, Austria
Hookipa Biotech GmbH

Terminated

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Metastatic

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Adenocarcinoma AJCC v7 | Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Prostate Adenocarcinoma With Neuroendocrine...

United States
Dana-Farber Cancer Institute
Janssen Research & Development, LLC

Active, not recruiting

Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer

Castration-resistant Prostate Cancer

United States
University of California, San Francisco
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

Metastatic Prostate Cancer | Castration Resistant Prostatic Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Progressive Disease | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma | High Grade Ovarian... and other conditions

United States
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Terminated

A Study of ASP1951 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Canada, Taiwan
University of Rochester
Roswell Park Cancer Institute

Completed

Cisplatin in Castration Resistant Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

HIV Infection | Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Metastatic Lung Non-Small Cell Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Melanoma | Recurrent Head and Neck Carcinoma | Recurrent Renal Cell Carcinoma | Advanced... and other conditions

United States
Hoffmann-La Roche

Completed

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)

Metastatic Prostate Cancer

United States, Belgium, France, United Kingdom, Canada, Korea, Republic of, China, Denmark, Greece, Ireland, Portugal, Spain, Italy, Brazil, Mexico, Australia, Thailand, Japan, Costa Rica, Israel, Russian Federation, Austria, Hungary, Norwa... and more
Aragon Pharmaceuticals, Inc.

Active, not recruiting

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN)

Prostatic Neoplasms

United States, Australia, France, Poland, United Kingdom, Germany, Taiwan, Spain, Belgium, Israel, Romania, Japan, Canada, Denmark, Finland, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Hungary, Austria, Sweden, Slovaki... and more
National Cancer Institute (NCI)

Suspended

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Advanced Solid Tumors | SCLC | HRD Cancer

United States
Bayer

Active, not recruiting

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Spain, Korea, Republic of, United Kingdom, Australia, Hong Kong, Singapore, Taiwan, Lithuania, Russian Federation, Turkey, France, Israel, Czechia, Italy, Germany, Finland, Austria, Poland, Hungary
Bayer

Active, not recruiting

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer (REASSURE)

Metastatic Castration-resistant Prostate Cancer

United States, Austria, Czechia, Israel, Italy, Germany, United Kingdom, France, Mexico, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Denmark, Sweden, Argentina, Portugal
National Cancer Institute (NCI)

Active, not recruiting

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Sarcoma | Metastatic Renal Cell Carcinoma | Metastatic Melanoma | Recurrent Renal Cell Carcinoma | Recurrent Melanoma | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Clinical Stage IV Cutaneous Melanoma... and other conditions

United States, Canada
M.D. Anderson Cancer Center

Completed

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
M.D. Anderson Cancer Center
Janssen Pharmaceutica

Active, not recruiting

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Aggressive Variant Prostate Carcinoma | Metastatic Prostate Neuroendocrine Carcinoma | Metastatic Prostate Small Cell Carcinoma

United States
University of California, San Francisco
National Cancer Institute (NCI); Prostate Cancer Foundation

Active, not recruiting

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer | Castration Levels of Testosterone | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer

United States
SOTIO Biotech AG
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

Hepatocellular Carcinoma | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Castration-resistant Prostate Cancer | Cutaneous Squamous Cell Carcinoma

Italy, Spain, France, Belgium, Czechia, United States, Poland, Georgia, Hungary
Epizyme, Inc.

Active, not recruiting

A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer (CELLO-1)

Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States, Spain, Belgium
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6)

Prostatic Neoplasms, Castration-Resistant | Prostatic Cancer, Castration-Resistant | Castration Resistant Prostatic Neoplasms | Androgen-Resistant Prostatic Neoplasms

United States, Canada
Kieuhoa Vo
Cannonball Kids' Cancer Foundation

Available

131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol

Neuroblastoma

United States
Pfizer
Astellas Pharma Inc

Active, not recruiting

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

United States
M.D. Anderson Cancer Center

Active, not recruiting

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Recurrent Breast Inflammatory Carcinoma | Stage IV Breast Inflammatory Carcinoma

United States
University of Wisconsin, Madison
Merck Sharp & Dohme LLC; Prostate Cancer Foundation; Madison Vaccines, Inc

Active, not recruiting

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Prostate Cancer | Metastatic Cancer | Castration-resistant Prostate Cancer

United States
Santa Chiara Hospital

Completed

Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer (CHEIRON)

Prostatic Neoplasms

Italy
Tvardi Therapeutics, Incorporated

Completed

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Breast Cancer

United States
Eli Lilly and Company

Active, not recruiting

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer (CYCLONE 2)

Prostate Cancer

Netherlands, United States, China, Australia, Japan, Spain, Korea, Republic of, Denmark, Germany, France, Romania
Bayer

Active, not recruiting

Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases

Prostatic Neoplasms, Castration-Resistant

Japan
Novartis Pharmaceuticals

Active, not recruiting

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

China
Novartis Pharmaceuticals

Active, not recruiting

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Ovarian Cancer

United States, Italy, United Kingdom, Malaysia, Taiwan, Turkey, Belgium, Canada, Spain, Singapore, Austria, Denmark, Korea, Republic of, Australia, China, France, Netherlands, Russian Federation, Germany, Argentina, Mexico, Finland, Portuga... and more
Stanford University
National Cancer Institute (NCI)

Completed

Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer

Multiple Myeloma | Recurrent Prostate Cancer | Plasmacytoma | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Bayer

Active, not recruiting

An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings (DEAR-EXT)

Non-metastatic Castration-resistant Prostate Cancer

United States
Aragon Pharmaceuticals, Inc.

Active, not recruiting

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Prostatic Neoplasms

United States, Australia, France, Germany, United Kingdom, Belgium, Spain, Argentina, South Africa, Japan, Canada, Netherlands, Korea, Republic of, Brazil, Russian Federation, Mexico

Search clinical trials for: Resistant Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations